My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 134

    1.

    Analysis of metabolic parameters as predictors of risk in the RENAAL study.

    Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM; RENAAL Study.

    Diabetes Care. 2003 May;26(5):1402-7.PMID: 12716796 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

    Kidney Int. 2004 Jun;65(6):2309-20.PMID: 15149345 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group.

    Arch Intern Med. 2003 Jul 14;163(13):1555-65.PMID: 12860578 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.

    Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Asian RENAAL Study Investigators.

    Diabetes Care. 2004 Apr;27(4):874-9.PMID: 15047641 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

    Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators.

    Kidney Int. 2003 Apr;63(4):1499-507.PMID: 12631367 [PubMed - indexed for MEDLINE]Related articles

    6.

    Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

    Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

    Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.PMID: 12612946 [PubMed - indexed for MEDLINE]Related articles

    7.

    Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

    Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM; RENAAL Investigators.

    Kidney Int Suppl. 2002 Dec;(82):S64-7.PMID: 12410858 [PubMed - indexed for MEDLINE]Related articles

    8.

    The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.

    Erdman DM, Cook CB, Greenlund KJ, Giles WH, El-Kebbi I, Ryan GJ, Gallina DL, Ziemer DC, Dunbar VG, Phillips LS.

    Diabetes Care. 2002 Jan;25(1):9-15.PMID: 11772894 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

    de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

    Kidney Int. 2006 May;69(9):1675-82.PMID: 16572114 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

    Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

    Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.PMID: 18070995 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

    Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.

    Diabetes Care. 2003 Mar;26(3):683-7.PMID: 12610022 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

    Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

    Pharmacoeconomics. 2006;24(6):549-58.PMID: 16761903 [PubMed - indexed for MEDLINE]Related articles

    13.

    Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM; RENAAL Study Group.

    J Am Soc Nephrol. 2004 Dec;15(12):3117-25.PMID: 15579515 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

    Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

    Clin Exp Nephrol. 2006 Sep;10(3):193-200.PMID: 17009077 [PubMed - indexed for MEDLINE]Related articles

    15.

    Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients.

    Romero P, Salvat M, Fernández J, Baget M, Martinez I.

    J Diabetes Complications. 2007 Mar-Apr;21(2):93-100.PMID: 17331857 [PubMed - indexed for MEDLINE]Related articles

    16.

    Losartan and end-organ protection--lessons from the RENAAL study.

    Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators.

    Clin Cardiol. 2005 Mar;28(3):136-42.PMID: 15813620 [PubMed - indexed for MEDLINE]Related articles

    17.

    Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.

    Egan B, Gleim G, Panish J.

    Curr Med Res Opin. 2004 Dec;20(12):1909-17.PMID: 15701209 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

    N Engl J Med. 2001 Sep 20;345(12):861-9.PMID: 11565518 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.

    Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B.

    Kidney Int Suppl. 2002 Dec;(82):S68-72.PMID: 12410859 [PubMed - indexed for MEDLINE]Related articles

    20.

    Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.

    Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ.

    Nephrology (Carlton). 2005 Oct;10(5):520-4.PMID: 16221106 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity